Realistically, a 5% tax rise should prompt a 5% spending cut, with the earning power lost to inflation adding more belt tightening. You can't squeeze blood from a stone. Workers have no money.

The market has been speculating as to whether the MannKind-Sanofi partnership will lead to a full-blown merger and acquisition.

The raised outlook reflects the continued strong performance of Vimizim and updated expectations. The market responded positively today.

December E-mini S&Ps (ESZ14 -0.75%) this morning are down -0.20% and European stocks are down -0.87% on global economic concerns.

Alnylam posts positive phase 2 results in open-label study.

Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the leagueof bigger players.